PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors.
Our key offerings include:
Transactions / deal negotiations;
Product / technology valuations;
Deal term advice;
Due diligence & expert reports;
Strategy formulation;
Alliance management; and
Expert opinion for litigation/arbitration cases.
PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Bioniche Life Sciences Inc
Bioniche Life Sciences Inc - The history of Bioniche Life Sciences Inc began in London, Ontario in 1979. Graeme McRae , Chairman, President & CEO, launched a small animal health products company called Vetrepharm with support from a group of Canadian veterinarians. The vision they shared was to develop innovative medicines and vaccines for animal health that would help to reduce the level of antibiotics commonly used in the livestock industry. Over the years, Bioniche Inc has evolved into a research-based, technology-driven Canadian biopharmaceutical company that discovers, develops, manufactures, and markets proprietary products for human and animal health markets worldwide. The company now employs approximately 200 people and has three principal reporting divisions: Human Health, Animal Health, and Food Safety. Corporate headquarters are located in Belleville, Ontario, with research, manufacturing, and marketing/sales facilities in Belleville; Montreal, Quebec; Athens, Georgia; Pullman, Washington; and Armidale, Australia. Bioniche Inc is now poised for a new level of growth, with an expanded global presence, and a portfolio of products and technologies in development that promises to have a profound impact on the converging world of human and animal health. Effective therapies for bladder cancer and potentially other cancer; a cattle Vaccine to help prevent E. coli O157:H7 infection; technologies to improve reproduction and potentially replace the use of antibiotics in livestock: these are key areas of strategic focus for Bioniche Inc.